EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Fatty acid Sources: 3

Omega-3 fatty acids

Also called: fish oil, EPA, DHA, ALA, krill oil, algal oil, n-3 fatty acids

Polyunsaturated fats with a double bond three carbons from the methyl end. ALA comes from plant oils such as flaxseed, soybean and canola; EPA and DHA come mainly from cold-water fish and are sold as fish, krill, cod liver and algal oils.

Category
Fatty acid
Forms
Fish, krill, cod liver and algal oils; supplied as natural triglycerides, free fatty acids, ethyl esters, re-esterified triglycerides or phospholipids (krill oil mainly phospholipids)
Strongest evidence
A Strong
Reviewed
2026-10-28

Class 1 Well studied in people. A 2018 meta-analysis (JAMA Cardiology) pooled 10 RCTs (77,917 participants) of omega-3 supplements versus placebo (8 trials) or open-label no treatment (2) for at least 1 year; all but one used EPA plus DHA. Two were factorial trials that also tested vitamin E or B vitamins. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied4 body areas · strongest grade A

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Omega-3 fatty acids does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Omega-3 fatty acids, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood triglyceride levelsAA 2020 review of 23 studies (43,998 participants) found EPA and DHA lowered triglycerides by about 15 percent but did not affect body fat or other blood lipids. [2]
Major cardiovascular eventsBResults differ by trial: VITAL (25,871 adults, 1 g/day) found no significant drop in combined major events; REDUCE-IT (8,179, 4 g/day icosapent ethyl) reported 25% fewer; STRENGTH (13,078, 4 g/day) found no significant benefit. [1]
Preterm birth (supplements in pregnancy)BA 2018 Cochrane review (70 RCTs, 19,927 women) reported 11% lower risk of birth before 37 weeks; a 2016 AHRQ review found pregnancies lasted slightly longer but no effect on risk of premature birth. [2]
Progression of age-related macular degenerationXAREDS2, with more than 4,000 participants, found that adding EPA and DHA to the AREDS supplement formula provided no additional benefit. [2]
Cognitive function in healthy older adultsXODS summarizes that trials found long-chain omega-3 supplementation does not affect cognitive function in healthy older adults; trials in people with Alzheimer's disease also found no benefit. [1]
DepressionCA 2021 review of 35 studies (1,964 participants) concluded that any effect may be too small to be meaningful; evidence quality was judged low or very low. [2]

Main constituents: Alpha-linolenic acid (ALA), from plant oils [1]; Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), long-chain marine omega-3s [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • A typical fish oil supplement provides about 1,000 mg fish oil, containing 180 mg EPA and 120 mg DHA. [1]
  • VITAL used 1 g/day (460 mg EPA and 380 mg DHA); REDUCE-IT used 4 g/day icosapent ethyl; STRENGTH used 4 g/day omega-3 carboxylic acids. [1]
  • Adequate Intake for ALA, adults 19 and older: 1.6 g/day for men and 1.1 g/day for women; 1.4 g/day in pregnancy and 1.3 g/day in lactation. No intake recommendations were set for EPA or DHA. [1]

Upper limits

  • The Institute of Medicine did not establish a UL for any omega-3s; it noted that 2-15 g/day EPA and/or DHA might increase bleeding time. [1]
  • FDA: dietary supplements providing no more than 5 g/day EPA and DHA are safe when used as recommended. [1]
  • EFSA: long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day appears to be safe. [1]
Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score E
    A: well known causeE: unlikely cause

    LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), for omega-3 fatty acids in general and for each prescription …

    Details and sources
  • Pregnancy and breastfeeding
    ODS: RCTs have not shown consistent benefits of maternal EPA and/or DHA supplementation during pregnancy for infant cognitive or visual development …

    2 statements in the profile.

    Details and sources
  • Interactions with medicines
    2 listed

    Warfarin and similar anticoagulants; Drugs metabolized by cytochrome P450 or carried by drug transporters

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    30 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Side effects are usually mild: unpleasant taste, bad breath, bad-smelling sweat, headache, heartburn, nausea and diarrhea. [2]
  • Two large trials found that 4 g/day slightly increased the risk of atrial fibrillation in people with cardiovascular disease or at high risk of it. [1]
  • Fish liver oils such as cod liver oil also contain vitamins A and D in amounts that vary by product; these vitamins can be harmful in excessive amounts. [2]
Interactions

Interactions

Known interactions of Omega-3 fatty acids
WithWhat happens
Warfarin and similar anticoagulantsHigh-dose fish oil has antiplatelet effects and might prolong clotting times (higher INR) with warfarin. Most research indicates 3-6 g/day fish oil does not significantly affect anticoagulant status; prescription omega-3 labels advise periodic INR monitoring. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Prescription omega-3 products differ in composition from typical omega-3 supplements and are tested and regulated as drugs, so their effects may not be the same as those of supplements. [2]
Regulation

Regulatory status

  • US: sold as dietary supplements. Several omega-3 products are approved as prescription drugs, used with diet, to lower very high triglyceride levels. [2]
  • US: FDA allows a qualified health claim that supplements containing EPA and DHA may reduce coronary heart disease risk, worded as supported by research that is not conclusive. [1]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Alpha-linolenic acid (ALA), from plant oils Fatty acids (omega-3 polyunsaturated) [P5]
  • Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), long-chain omega-3s Fatty acids (omega-3 polyunsaturated) [P5]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 30 entries naming omega-3 fatty acids, EPA or DHA (earliest NDI 19 submitted 1997-12-22; most recent NDI 1457 submitted 2026-01-14). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
  • 4 further entries name krill oil or krill oil extracts without naming omega-3, EPA or DHA (earliest NDI 155 submitted 2002-03-13; most recent NDI 1360 submitted 2024-09-12). [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC carcinogenicity evaluation of omega-3 fatty acids, fish oil, krill oil or algal oil was found (IARC Monographs list of classifications checked 2026-10-29). [P2]
  • No NTP carcinogenicity technical report on omega-3 fatty acids, fish oil, krill oil or algal oil was found (NTP technical reports list checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), for omega-3 fatty acids in general and for each prescription product (chapter last updated April 8, 2017). [P7]

Interactions with medicines

  • Warfarin and similar anticoagulants: Fish oil can have antiplatelet effects at high doses and might prolong clotting times (elevated INR) with warfarin; most research indicates 3-6 g/day fish oil does not significantly affect anticoagulant status. Package inserts for omega-3 pharmaceuticals say patients taking them with anticoagulants should be monitored periodically for changes in INR. [P5]
  • Drugs metabolized by cytochrome P450 or carried by drug transporters: LiverTox states omega-3 fatty acids have little effect on hepatic cytochrome P450 or drug transporter activity. [P7]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition-based exemption under 111.75(a)(1)(ii). [P4]
  • EPA and DHA content per serving — ODS: formulations of omega-3 dietary supplements vary widely (a typical 1,000 mg fish oil supplement contains 180 mg EPA and 120 mg DHA). [P5]
  • Vitamin A and vitamin D content (fish liver oils such as cod liver oil) — NCCIH: fish liver oils contain vitamins A and D in amounts that vary by product, and these vitamins can be harmful in excessive amounts. [P6]

Supply and conservation

  • Long-chain omega-3 supplements are made from fish oil, krill oil, cod liver oil and, for vegetarian products, algal oil; algal oil products usually provide about 100-300 mg DHA and some contain EPA. [P5]

Absorption in people

  • Re-esterified triglycerides, natural triglycerides and free fatty acids have somewhat higher bioavailability than ethyl esters, but consumption of all forms significantly increases plasma EPA and DHA levels. [P5]
  • Krill oil contains omega-3s mainly as phospholipids; some studies suggest somewhat higher bioavailability than fish-oil omega-3s, while others do not. [P5]
  • In a small study, the bioavailability of DHA from algal oil was equivalent to that from cooked salmon. [P5]
  • Conversion of ALA to EPA and then DHA, mainly in the liver, is very limited, with reported rates of less than 15%. [P5]
  • During absorption, icosapent ethyl (a prescription EPA ethyl ester) is de-esterified to EPA; omega-3 fatty acids are metabolized in the liver by beta-oxidation. [P7]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • ODS: RCTs have not shown consistent benefits of maternal EPA and/or DHA supplementation during pregnancy for infant cognitive or visual development; long-chain omega-3 supplements, particularly DHA, have been shown to reduce the risk of preterm and early preterm birth. [P5]
  • NCCIH: a 2020 review found limited evidence that omega-3 supplementation during pregnancy has positive effects on cognitive development; an AHRQ review found supplements had no effect on the risk of premature birth. [P6]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (list last updated 2026-07-23 per page data; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals (no printed update date captured; page last modified 2026-10-24 per page metadata), 2026-10-24. ods.od.nih.gov
  6. NCCIH. Omega-3 Supplements: What You Need To Know (Last Updated: November 2024), 2024-11. nccih.nih.gov
  7. NIH LiverTox. Omega-3 Fatty Acids (Last Update: April 8, 2017), 2017-04-08. ncbi.nlm.nih.gov
Sources

Sources

  1. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals (no printed update date captured; page last modified 2026-10-24 per page metadata), 2026-10-24. ods.od.nih.gov
  2. NCCIH. Omega-3 Supplements: What You Need To Know (Last Updated: November 2024), 2024-11. nccih.nih.gov
  3. Aung T, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol 2018;3(3):225-234 (PMID 29387889), 2018-03-01. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in fatty acid: Algal oil (DHA and EPA) · Arachidonic acid · Argan oil · Conjugated linoleic acid (CLA) · Evening primrose oil · GLA oils (borage and blackcurrant seed oil) · Krill oil · Linoleic acid · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.